Peginterferon alfa‐2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
Lennox J. Jeffers, William Cassidy, Charles D. Howell, Sylvia Hu, K. Rajender Reddy – 27 May 2004 – Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa‐based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa‐2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1.